STAT5 Activation Enhances Adoptive Therapy Combined with Peptide Vaccination by Preventing PD-1 Inhibition

Area of Science:

• Immunology
• Cancer Therapy
• Cell Biology

Background:

• Adoptive cell therapy (ACT) shows promise for cancer treatment.
• STAT5 is crucial for T-cell proliferation and differentiation.
• Combining ACT with vaccination strategies can enhance antitumor responses.

Purpose of the Study:

• To investigate the combination of ACT with a peptide vaccination strategy (TriVax).
• To explore the role of constitutively active STAT5 (CA-STAT5) in engineered T cells for cancer therapy.
• To assess the impact of CA-STAT5 on T-cell function and antitumor efficacy in a melanoma model.

Main Methods:

• Engineered CD8 T cells expressing a gp100 T-cell receptor (TCR) were generated using retroviral transduction.
• Some T cells were co-transduced to express CA-STAT5.
• Functional assays and flow cytometry were used to assess T-cell activity.
• Mice bearing B16F10 melanoma were treated with ACT and TriVax vaccination.

Main Results:

• TriVax selectively expanded gp100-specific TCR-transduced T cells.
• CA-STAT5 expression increased T-cell expansion, polyfunctionality, and persistence.
• CA-STAT5 reduced PD-1 expression on T cells, indicating decreased exhaustion.
• The combination therapy demonstrated potent antitumor effects in a melanoma model, amplified by CA-STAT5.
• CA-STAT5 attenuated the PD-1/PD-L1 inhibitory pathway, enhancing antitumor activity.

Conclusions:

• TCR-transduced CD8 T cells expand antigen-dependently with TriVax vaccination.
• CA-STAT5 enhances T-cell proliferation, persistence, and antitumor efficacy.
• CA-STAT5 promotes resistance to PD-1/PD-L1-mediated inhibition in antitumor T cells.